Silverberg Bernstein Capital Management LLC Increases Holdings in MediWound Ltd. (NASDAQ:MDWD)

Silverberg Bernstein Capital Management LLC grew its holdings in MediWound Ltd. (NASDAQ:MDWD - Free Report) by 13.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 103,944 shares of the biopharmaceutical company's stock after purchasing an additional 12,060 shares during the quarter. MediWound comprises about 1.5% of Silverberg Bernstein Capital Management LLC's portfolio, making the stock its 19th biggest position. Silverberg Bernstein Capital Management LLC owned approximately 0.96% of MediWound worth $1,613,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MDWD. R Squared Ltd bought a new stake in MediWound in the fourth quarter worth approximately $32,000. GAMMA Investing LLC grew its position in shares of MediWound by 1,507.1% during the 1st quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 1,703 shares during the period. Russell Investments Group Ltd. increased its stake in shares of MediWound by 154.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 1,162 shares in the last quarter. Bank of America Corp DE boosted its stake in MediWound by 38.0% during the fourth quarter. Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company's stock worth $141,000 after acquiring an additional 2,178 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in MediWound by 7.3% in the fourth quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company's stock worth $193,000 after purchasing an additional 739 shares during the period. 46.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MDWD has been the subject of several research reports. Oppenheimer began coverage on MediWound in a research note on Monday. They issued an "outperform" rating and a $34.00 target price for the company. Alliance Global Partners initiated coverage on MediWound in a report on Friday, May 2nd. They set a "buy" rating and a $25.00 price objective for the company. Wall Street Zen upgraded MediWound to a "sell" rating in a report on Friday, March 21st. HC Wainwright set a $31.00 price target on shares of MediWound and gave the company a "buy" rating in a research report on Thursday, May 22nd. Finally, Craig Hallum initiated coverage on shares of MediWound in a research note on Friday, February 28th. They set a "buy" rating and a $39.00 price target for the company. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $31.80.

MediWound Stock Up 0.5%

NASDAQ:MDWD traded up $0.11 during trading hours on Wednesday, hitting $21.70. 42,836 shares of the company traded hands, compared to its average volume of 91,624. MediWound Ltd. has a one year low of $12.78 and a one year high of $24.00. The company has a market cap of $234.53 million, a PE ratio of -7.48 and a beta of 0.30. The firm's 50-day simple moving average is $18.09 and its 200-day simple moving average is $17.85.

MediWound (NASDAQ:MDWD - Get Free Report) last released its quarterly earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.58. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. The company had revenue of $3.96 million for the quarter, compared to analyst estimates of $5.20 million. During the same period last year, the firm earned ($1.05) earnings per share. As a group, equities research analysts expect that MediWound Ltd. will post -2.66 EPS for the current year.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.